Cargando…

Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer

Chemokines are involved in the regulation of immune balance and in triggering an immune response. CXCL1 and CXCL8 belong to the ELR-motif-containing group of CXC chemokines, which, in breast cancer (BC), stimulate angiogenesis and increase migration and invasiveness of tumor cells. The aim of this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Motyka, Joanna, Gacuta, Ewa, Kicman, Aleksandra, Kulesza, Monika, Ławicki, Paweł, Ławicki, Sławomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693547/
https://www.ncbi.nlm.nih.gov/pubmed/36431173
http://dx.doi.org/10.3390/jcm11226694
_version_ 1784837571220602880
author Motyka, Joanna
Gacuta, Ewa
Kicman, Aleksandra
Kulesza, Monika
Ławicki, Paweł
Ławicki, Sławomir
author_facet Motyka, Joanna
Gacuta, Ewa
Kicman, Aleksandra
Kulesza, Monika
Ławicki, Paweł
Ławicki, Sławomir
author_sort Motyka, Joanna
collection PubMed
description Chemokines are involved in the regulation of immune balance and in triggering an immune response. CXCL1 and CXCL8 belong to the ELR-motif-containing group of CXC chemokines, which, in breast cancer (BC), stimulate angiogenesis and increase migration and invasiveness of tumor cells. The aim of this study was to evaluate CXCL1, CXCL8 and comparative marker CA 15-3 plasma concentrations in BC patients with luminal subtypes A and B. The study group consisted of 100 patients with BC, and the control group of 50 subjects with benign breast lesions and 50 healthy women. Chemokines concentrations were determined by ELISA method; CA15-3-by CMIA. Concentrations of CXCL8 and CA15-3 were significantly higher in BC total group and luminal B (for CA15-3 also in luminal A) subtype of BC than in healthy controls and subjects with benign lesions. In the total BC group, the highest SE, PPV and NPV were observed for CXCL8 (70%, 77.78%, 50%, resp.). A combined analysis of tested chemokines with CA 15-3 increased SE and NPV values (96%, 69.23%, resp.). The diagnostic power of the test (measured by area under ROC curve (AUC)) showed the highest value for CXCL8 in the total BC group (0.6410), luminal A (0.6120) and B subgroup of BC (0.6700). For the combined parameter, the AUC was increasing and reached the highest value for CXCL1 + CXCL8 + CA15-3 combination (0.7024). In light of these results, we suggest that CXCL8 could be used as an additional diagnostic marker that would positively influence the diagnostic utility of CA 15-3, especially in luminal B subtype of BC.
format Online
Article
Text
id pubmed-9693547
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96935472022-11-26 Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer Motyka, Joanna Gacuta, Ewa Kicman, Aleksandra Kulesza, Monika Ławicki, Paweł Ławicki, Sławomir J Clin Med Article Chemokines are involved in the regulation of immune balance and in triggering an immune response. CXCL1 and CXCL8 belong to the ELR-motif-containing group of CXC chemokines, which, in breast cancer (BC), stimulate angiogenesis and increase migration and invasiveness of tumor cells. The aim of this study was to evaluate CXCL1, CXCL8 and comparative marker CA 15-3 plasma concentrations in BC patients with luminal subtypes A and B. The study group consisted of 100 patients with BC, and the control group of 50 subjects with benign breast lesions and 50 healthy women. Chemokines concentrations were determined by ELISA method; CA15-3-by CMIA. Concentrations of CXCL8 and CA15-3 were significantly higher in BC total group and luminal B (for CA15-3 also in luminal A) subtype of BC than in healthy controls and subjects with benign lesions. In the total BC group, the highest SE, PPV and NPV were observed for CXCL8 (70%, 77.78%, 50%, resp.). A combined analysis of tested chemokines with CA 15-3 increased SE and NPV values (96%, 69.23%, resp.). The diagnostic power of the test (measured by area under ROC curve (AUC)) showed the highest value for CXCL8 in the total BC group (0.6410), luminal A (0.6120) and B subgroup of BC (0.6700). For the combined parameter, the AUC was increasing and reached the highest value for CXCL1 + CXCL8 + CA15-3 combination (0.7024). In light of these results, we suggest that CXCL8 could be used as an additional diagnostic marker that would positively influence the diagnostic utility of CA 15-3, especially in luminal B subtype of BC. MDPI 2022-11-12 /pmc/articles/PMC9693547/ /pubmed/36431173 http://dx.doi.org/10.3390/jcm11226694 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Motyka, Joanna
Gacuta, Ewa
Kicman, Aleksandra
Kulesza, Monika
Ławicki, Paweł
Ławicki, Sławomir
Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer
title Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer
title_full Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer
title_fullStr Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer
title_full_unstemmed Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer
title_short Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer
title_sort plasma levels of cxc motif chemokine 1 (cxcl1) and chemokine 8 (cxcl8) as diagnostic biomarkers in luminal a and b breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693547/
https://www.ncbi.nlm.nih.gov/pubmed/36431173
http://dx.doi.org/10.3390/jcm11226694
work_keys_str_mv AT motykajoanna plasmalevelsofcxcmotifchemokine1cxcl1andchemokine8cxcl8asdiagnosticbiomarkersinluminalaandbbreastcancer
AT gacutaewa plasmalevelsofcxcmotifchemokine1cxcl1andchemokine8cxcl8asdiagnosticbiomarkersinluminalaandbbreastcancer
AT kicmanaleksandra plasmalevelsofcxcmotifchemokine1cxcl1andchemokine8cxcl8asdiagnosticbiomarkersinluminalaandbbreastcancer
AT kuleszamonika plasmalevelsofcxcmotifchemokine1cxcl1andchemokine8cxcl8asdiagnosticbiomarkersinluminalaandbbreastcancer
AT ławickipaweł plasmalevelsofcxcmotifchemokine1cxcl1andchemokine8cxcl8asdiagnosticbiomarkersinluminalaandbbreastcancer
AT ławickisławomir plasmalevelsofcxcmotifchemokine1cxcl1andchemokine8cxcl8asdiagnosticbiomarkersinluminalaandbbreastcancer